What is the appropriate diagnostic work‑up and initial treatment for a patient with suspected autoimmune glomerulonephritis?

Diagnostic Work-Up and Initial Treatment for Suspected Autoimmune Glomerulonephritis

When autoimmune glomerulonephritis is suspected based on rapid kidney function decline with active urinary sediment, immediately obtain autoimmune serologies (ANCA, anti-GBM antibodies, ANA, complement levels) and exclude infection, then start immunosuppressive therapy without waiting for kidney biopsy results if clinical presentation and positive serology support the diagnosis. 1

Diagnostic Algorithm for Rapidly Progressive Glomerulonephritis

Initial Evaluation

• Urinalysis findings: Confirm urine dipstick positive for protein and blood, with sediment showing glomerular hematuria and/or pyuria without infection 1
• Autoimmune serologies: Order ANCA (MPO and PR3), anti-GBM antibodies, ANA, and complement levels immediately 1
• Extrarenal manifestations: Assess for pulmonary hemorrhage, upper respiratory symptoms, rash, arthritis, or other systemic vasculitis features 1
• Infection exclusion: Rule out infection with as much certainty as possible before initiating significant immunosuppression 1

Kidney Biopsy Strategy

• Biopsy timing: Obtain kidney biopsy when feasible for diagnosis confirmation and prognosis, but do not delay treatment while waiting for biopsy results if clinical presentation is compatible with ANCA vasculitis and serology is positive 1
• Biopsy provides: Histopathologic classification (focal, crescentic, mixed, or sclerotic class) which informs prognosis but should not prevent treatment initiation 1

Initial Treatment by Disease Type

ANCA-Associated Vasculitis (Most Common Cause of RPGN)

Induction Therapy Selection

Choose between rituximab and cyclophosphamide based on disease severity and patient factors: 1

Cyclophosphamide is preferred when: 1

• Severe glomerulonephritis with serum creatinine >4 mg/dL (>354 μmol/L)
• Consider combination of two intravenous pulses of cyclophosphamide with rituximab in this setting 1

Rituximab may be preferred when: 1

• Less severe kidney impairment (serum creatinine <4 mg/dL)
• Younger patients desiring fertility preservation
• PR3-ANCA positive patients (who have higher relapse rates)

Glucocorticoid Dosing

• Reduced-dose glucocorticoid regimens are now recommended based on the PEXIVAS trial, which demonstrated that lower glucocorticoid doses can be used safely compared to traditional high-dose regimens 1
• Start glucocorticoids immediately when diagnosis is suspected 1

Plasma Exchange

• Do not use plasma exchange routinely in ANCA-associated vasculitis 1
• Exception: Use plasma exchange if ANCA vasculitis overlaps with anti-GBM antibody disease (double-positive patients) 1

Anti-GBM Glomerulonephritis

Immediate Treatment Protocol

Start treatment without delay once anti-GBM disease is confirmed or highly suspected: 1, 2, 3

• Initiate immediately: High-dose corticosteroids plus plasma exchange while awaiting confirmation 1, 2
• Add cyclophosphamide: Once infection is adequately ruled out and diagnosis is confirmed 1, 2, 3
• Complete regimen: Cyclophosphamide, corticosteroids, and plasma exchange for all patients except those who are dialysis-dependent at presentation with 100% crescents on adequate biopsy and no pulmonary hemorrhage 1, 3

Treatment Exceptions

• Do not treat patients who are dialysis-dependent with 100% crescents on biopsy and no extrarenal manifestations, as renal recovery is unlikely 1, 3
• Double-positive patients (anti-GBM plus ANCA) require maintenance immunosuppression similar to ANCA vasculitis due to higher relapse risk 3

Maintenance Therapy

• No maintenance immunosuppression is recommended for classic anti-GBM disease, as relapses are rare 1, 3
• Defer kidney transplantation until anti-GBM antibodies are undetectable for minimum 6 months 1

Critical Pitfalls to Avoid

Timing Errors

• Never delay treatment while pursuing exhaustive infection work-up in patients with high pre-test probability of autoimmune GN 2
• Do not wait for kidney biopsy results to start therapy if MPO- or PR3-ANCA is positive and clinical presentation is compatible 1

Treatment Selection Errors

• Limited rituximab data exists for severely impaired kidney function (serum creatinine >4 mg/dL); cyclophosphamide remains preferred in this setting 1
• Avoid etanercept as adjunctive therapy in ANCA vasculitis 1
• Do not change immunosuppression based on ANCA titer changes alone 1

Infection Risk

• Approximately 16% of febrile anti-GBM patients are also MPO-ANCA positive; this double-positive status mandates maintenance immunosuppression but does not explain fever 2
• The aggressive immunosuppression required carries substantial infection risk, requiring careful balance between early treatment and infection exclusion 2, 3